- FDA approves five-day dosing regimen of Eisai's Dacogen for MDS
- FDA refuses to file NDA for Adventrx's investigational NSCLC treatment
- FDA grants ImmunoGen's investigational skin cancer compound orphan drug status
- FDA grants permission to Synta to resume testing of elesclomol in cancer
- Boxed warning added to Plavix label regarding possible reduced efficacy in certain patients
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
Home :: Hematology/Oncology :: Hematology/Oncology Conferences
30th Annual SABCS
December 12-16, 2007 San Antonio, Texas- Completion axillary dissection may not be required after positive sentinel node biopsy
- Denosumab increases BMD in women with breast cancer receiving AI therapy, findings indicate
- Continuation of tamoxifen beyond standard 5 years reduces breast cancer recurrence, preliminary data show
- Anastrozole appears superior to tamoxifen in reducing risk of recurrence in patients with early breast cancer, data show
- Docetaxel plus cyclophosphamide improves overall survival better than standard chemotherapy in women with breast cancer, data show
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- PSA screening controversy increases with release of mortality studies with conflicting results, modest benefits
- Researchers evaluate predictors of re-excision, residual disease in women with close, positive margins following partial mastectomy
- Men with biopsy Gleason score 7, tertiary grade 5 disease face similar risk of PSA recurrence as men with higher Gleason score disease, study data suggest
- Addition of radiotherapy to endocrine therapy has little negative long-term effect on QOL among men with prostate cancer, study shows
- Radiotherapy, chemotherapy increase risks of second malignancy, cardiovascular disease similar to smoking in patients with testicular cancer, researchers report
- Radiation therapy for prostate cancer raises bladder, rectal cancer risk, study indicates
- ACE inhibitors, ARBs may reduce risk of nonmelanoma skin cancer in high-risk patients, researchers report
- Dietary intervention appears useful in men with prostate cancer
- Many survivors of childhood cancer do not get cancer-focused aftercare, study shows
